Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial

Journal of Infectious Diseases

Volumn 212, Issue 4, 2015, Pages 531-541

  Schuind, Anne ^a   Segall, Nathan ^b   Drame, Mamadou ^a   Innis, Bruce L ^a  

^a GLAXOSMITHKLINE   (United States)

^b Clinical Research Atlanta   (United States)

Author keywords

AS03; cell culture; influenza A(H5N1); pandemic influenza vaccine

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; PLACEBO; ALPHA TOCOPHEROL; ASO3B ADJUVANT; DRUG COMBINATION; POLYSORBATE; SQUALENE; VIRUS ANTIBODY;

ADULT; ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; BACKACHE; CELL LINE; CONTROLLED STUDY; COUGHING; DRUG EFFECT; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; EB66 CELL LINE; FATIGUE; FEASIBILITY STUDY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INDONESIA; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; INJECTION SITE PAIN; MALE; MULTICENTER STUDY; MYALGIA; NONHUMAN; NORMAL HUMAN; NOSE OBSTRUCTION; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION; VIRUS STRAIN; ADOLESCENT; ANIMAL; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; DUCK; EMBRYOLOGY; EMBRYONIC STEM CELL; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); INFLUENZA, HUMAN; MIDDLE AGED; SINGLE BLIND PROCEDURE; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALPHA-TOCOPHEROL; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; DRUG COMBINATIONS; DUCKS; EMBRYONIC STEM CELLS; FEMALE; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; POLYSORBATES; SINGLE-BLIND METHOD; SQUALENE; YOUNG ADULT;

EID: 84939636647     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv091     Document Type: Article

References (26)

1. Taubenberger JK, Morens DM. Influenza: the once and future pandemic. Public Health Rep Wash DC 1974 2010; 125(suppl 3):S16-26.
2. World Health Organization (WHO). WHO activities in avian influenza and pandemic influenza preparedness. Geneva: WHO, 2007. http://www.who.int/influenza/resources/documents/WHOCDSEPRGIP20066.pdf. Accessed 19 April 2014.
3. Rebmann T, Zelicoff A. Vaccination against influenza: role and limitations in pandemic intervention plans. Expert Rev Vaccines 2012; 11:1009-19.
4. Perdue ML, Arnold F, Li S, et al. The future of cell culture-based influenza vaccine production. Expert Rev Vaccines 2011; 10:1183-94.
5. Montomoli E, Khadang B, Piccirella S, et al. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production. Expert Rev Vaccines 2012; 11:587-94.
6. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343-51.
7. Langley JM, Frenette L, Ferguson L, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010; 201:1644-53.
8. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9.
9. Chu DW-S, Hwang S-J, Lim FS, et al. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009; 27:7428-35.
10. Langley JM, Risi G, Caldwell M, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 2011; 203:1729-38.
11. Diéz-Domingo J, Garcés-Sanchez M, Baldó J-M, et al. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Pediatr Infect Dis J 2010; 29:e35-46.
12. Nolan T, Izurieta P, Lee B-W, et al. Heterologous prime-boost vaccination using an H5N1-AS03-adjuvanted influenza vaccine in infants and children under 3 years of age. J Infect Dis 2014; 210:1800-10.
13. Center for Biologics Evaluation and Research. Vaccines guidance. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. http://www.fda.gov/BiologicsBlood Vaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074786.htm. Accessed 02 January 2014.
14. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004; 103:163-71.
15. Kendal A, Pereira M, Skehel J. Hemagglutination inhibition. Concepts and procedures for laboratory-based influenza surveillance. Atlanta, GA: Centers for Disease Control and Prevention and Pan-American Health Organization, 1985.
16. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43.
17. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004; 103:91-5.
18. Reed L, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 1938; 27:493-7.
19. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001; 19:1732-7.
20. Jennings LC, Monto AS, Chan PKS, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008; 8:650-8.
21. Lasko B, Reich D, Madan A, Roman F, Li P, Vaughn D. Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults. J Infect Dis 2011; 204:574-81.
22. Risi G, Frenette L, Langley JM, et al. Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months. Vaccine 2011; 29:6408-18.
23. Kosalaraksa P, Jeanfreau R, Frenette L, et al. AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase II/III randomized, placebo-controlled, observer-blind trial. J Infect Dis 2015; 211:801-10.
24. Feng S-Z, Jiao P-R, Qi W-B, Fan H-Y, Liao M. Development and strategies of cell-culture technology for influenza vaccine. Appl Microbiol Biotechnol 2011; 89:893-902.
25. Brown SW, Mehtali M. The avian EB66(R) cell line, application to vaccines, and therapeutic protein production. PDA J Pharm Sci Technol PDA 2010; 64:419-25.
26. Olivier S, JacobyM, Brillon C, et al. EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity. MAbs 2010; 2:405-15.